Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ICU MEDICAL INC/DE (ICUI)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B | $1.27B | $1.40B | $1.29B | $379.4M | $341.7M | $309.3M | $313.7M | $316.9M | $302.2M | $283.0M | $229.0M | $204.7M | $188.1M |
| Gross profit | $822.0M | $824.8M | $739.9M | $697.8M | $491.5M | $461.5M | $471.9M | $570.0M | $426.1M | $201.4M | $180.8M | $151.4M | $154.7M | $156.5M | $142.4M | $129.0M | $106.3M | $89.8M | $78.2M |
| Research & development | $87.5M | $88.6M | $85.3M | $93.0M | $47.5M | $42.9M | $48.6M | $52.9M | $51.3M | $13.0M | $15.7M | $18.3M | $12.4M | $10.6M | $8.6M | $4.7M | $2.6M | $4.8M | $8.1M |
| Operating expenses | $779.2M | $781.8M | $717.0M | $740.7M | $368.2M | $363.3M | $364.5M | $540.3M | $439.4M | $118.5M | $112.2M | $112.4M | $102.8M | $95.2M | $77.1M | $81.3M | $70.8M | $58.4M | $53.6M |
| Operating income | $42.8M | $43.0M | $22.8M | −$42.9M | $123.2M | $98.2M | $107.4M | $29.8M | −$13.3M | $82.9M | $68.6M | $39.0M | $51.9M | $61.3M | $65.2M | $47.7M | $35.4M | $31.4M | $24.6M |
| EBITDAderived | $243.6M | $262.5M | $251.6M | $192.3M | $212.9M | $183.8M | $184.3M | $104.5M | $53.3M | $102.0M | $86.6M | $58.5M | $71.5M | $80.3M | $83.5M | $65.0M | $51.1M | $45.6M | $36.4M |
| Net income | $732,000 | −$117.7M | −$29.7M | −$74.3M | $103.1M | $86.9M | $101.0M | $28.8M | $68.6M | $63.1M | $45.0M | $26.3M | $40.4M | $41.3M | $44.7M | $29.9M | $25.0M | $24.3M | $23.1M |
| Basic EPSper diluted share | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.86 | $4.16 | $4.90 | $1.41 | $3.50 | $3.90 | $2.84 | $1.72 | $2.75 | $2.90 | $3.23 | $2.20 | $1.70 | $1.72 | $1.62 |
| Diluted EPSper diluted share | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 | $2.73 | $1.68 | $2.65 | $2.80 | $3.15 | $2.16 | $1.67 | $1.67 | $1.51 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 22, 2026Form 4 | Woolson DanielPresident | SellCommon Stock | 2.1K | $132.21 | $280.7K | 22.5K |
| May 14, 2026Form 4 | Sanzone Virginia RuthVP, General Counsel | SellCommon Stock | 2.4K | $124.08 | $303.6K | 19.5K |
| May 12, 2026Form 4 | Greenberg David C.Director | SellCommon Stock | 2.4K | $122.91 | $297.9K | 8.0K |
| Nov 25, 2025Form 4 | Woolson DanielVP, GM-Infusion Capital | SellCommon Stock | 2.9K | $152.35 | $441.4K | 11.3K |
| Nov 11, 2025Form 4 | Sanzone Virginia RuthVP, General Counsel | SellCommon Stock | 930 | $142.35 | $132.4K | 5.5K |